- Trial phase
- Phase 2
- Time to market
- At least 4-6 years. Phase 2 primary completion is estimated March 2028, followed by Phase 3 trials and regulatory filing, putting potential approval in the 2030-2032 timeframe if all goes well.
- Why 3/10
- No hard binary catalyst is scheduled within the next ~12 months. The Phase 2 dose-finding trial (NCT07752979) has an estimated primary completion of March 2028, and there is no PDUFA or pivotal readout on the horizon. ABBV-295 is an early-stage program at a mega-cap company, making it a very small part of AbbVie's overall value.
The next catalyst is the Phase 2 topline readout, estimated around March 2028. For a mega-cap like AbbVie, even a strong Phase 2 result would be a modest share-price driver. Watch for any interim data presentations at medical conferences in 2027 and for Gubra milestone announcements tied to Phase 2 progress.
Price Chart
Executive Summary
ABBV-295 is an investigational long-acting amylin analog being developed by AbbVie (NYSE: ABBV) for obesity, licensed from Danish biotech Gubra in March 2025 for $350M upfront and up to $1.875B in milestones. Phase 1 data showed 7.8%-9.8% weight loss at 12 weeks with an 11-12 day half-life, supporting once-weekly or less frequent dosing. A Phase 2 dose-finding trial (NCT07752979) began recruiting in August 2026 with an estimated primary completion of March 2028. The drug is early-stage and represents a very small part of AbbVie's massive pipeline, with no near-term binary catalyst.
How It Works
ABBV-295 is a synthetic, long-acting version of amylin, a natural hormone released by the pancreas after meals that signals the brain to feel full and suppress appetite. It activates amylin and calcitonin receptors, working through a different pathway than popular GLP-1 weight-loss drugs like Ozempic and Wegovy.
Trial Status
Phase 1 completed with positive topline results announced March 9, 2026, and detailed data presented at EASD on September 30, 2026. Phase 2 dose-finding study (NCT07752979) began August 2026, is actively recruiting approximately 360 participants across 63 sites in 2 countries, with a 32-week primary endpoint and estimated primary completion in February/March 2028.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 topline readout estimated March 2028 (primary completion of primary endpoint)
- Potential interim data presentations at medical conferences in 2027 conferences
- Gubra milestone milestone achievement announcements tied to Phase 2 progress
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report